keyword
https://read.qxmd.com/read/38634770/proton-pump-inhibitors-increase-the-risk-of-carbapenem-resistant-enterobacteriaceae-colonization-by-facilitating-the-transfer-of-antibiotic-resistance-genes-among-bacteria-in-the-gut-microbiome
#1
JOURNAL ARTICLE
Imchang Lee, Jae-Won Jo, Heung-Jeong Woo, Ki Tae Suk, Seung Soon Lee, Bong-Soo Kim
Carbapenem-resistant Enterobacteriaceae (CRE) pose a global health threat; however, there is still limited understanding of the risk factors and underlying mechanisms of CRE colonization in the gut microbiome. We conducted a matched case-control study involving 282 intensive care unit patients to analyze influencing covariates on CRE colonization. Subsequently, their effects on the gut microbiome were analyzed in a subset of 98 patients (47 CRE carriers and 51 non-CRE carriers) using whole metagenome sequences...
2024: Gut Microbes
https://read.qxmd.com/read/38633840/switching-from-immediate-to-extended-release-cysteamine-in-patients-with-nephropathic-cystinosis-from-clinical-trials-to-clinical-practice
#2
JOURNAL ARTICLE
Gema Ariceta, Fernando Santos, Andrés López Muñiz, Alvaro Hermida, Maria Luisa Matoses, Ana Ventura, Paloma Leticia Martin-Moreno, Esther González, Laura Acuña, Elisa Giner, Julia Vara
BACKGROUND: The purpose of this study is to evaluate the effectiveness and safety of switching from immediate-release (IR) to extended-release (ER) cysteamine in patients with nephropathic cystinosis (NC) in Spain. METHODS: We conducted an observational, retrospective, multicentre study in NC patients who received IR cysteamine for at least 12 months, switched to ER cysteamine, and received it for at least 6 months before inclusion. RESULTS: Data were collected from nine patients (four children, five adults) 36 months before and after the switch...
April 2024: Clinical Kidney Journal
https://read.qxmd.com/read/38629502/influence-of-novel-cyp2c-haplotype-on-proton-pump-inhibitor-pharmacokinetics-in-children
#3
JOURNAL ARTICLE
Kathryn E Kyler, Andrea Gaedigk, Susan Abdel-Rahman, Vincent S Staggs, Robin E Pearce, Paul Toren, J Steven Leeder, Valentina Shakhnovich
In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by CYP2C19. In a cohort of 41 children aged 6-21 participating in a PPI pharmacokinetic study, effects of the CYP2C:TG allele were assessed by fitting two linear regression models for each of the six PK outcomes assessed, the second of which accounted for the presence of the CYP2C:TG allele...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38629331/a-new-predictive-scoring-model-for-globus-pharyngeus-in-patients-with-gastroesophageal-reflux-disease
#4
JOURNAL ARTICLE
Abdulaziz S Alshahrani, Faris Almasabi
BACKGROUND: Globus pharyngeus is a clinical condition, wherein, a patient senses a lump or a foreign body in the throat with a tightening or choking feeling. A strong association between globus pharyngeus and gastroesophageal reflux disease (GERD) was reported. Therefore, we sought to investigate the predictive factors of globus pharyngeus in patients with established GERD and fit a predictive scoring model for globus pharyngeus. METHODS: In this case-control study, 143 patients having globus pharyngeus along with GERD ( case ) and 109 patients having globus pharyngeus without GERD ( control ) were enrolled...
April 17, 2024: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://read.qxmd.com/read/38629191/safety-tolerability-and-pharmacokinetics-of-anaprazole-a-novel-proton-pump-inhibitor-in-healthy-chinese-subjects
#5
JOURNAL ARTICLE
Fangfang Wang, Xiaoye Niu, Fei Liu, Xifeng Ma, Fang Cheng, Haiyan Xu, Li Wang, Yanjun Xu, Haiyan Li
Anaprazole, a newly developed oral proton pump inhibitor, was evaluated for safety, tolerability, and pharmacokinetics in healthy Chinese subjects. This study involved administering either anaprazole sodium enteric-coated tablet or placebo, followed by monitoring the incidence and severity of any adverse events (AEs). The pharmacokinetic parameters of anaprazole, its isomer, and main metabolisms were determined. The results showed that both single-dose (2.5-120 mg) and multiple-dose (20 mg once daily, 40 mg once daily, or 20 mg twice daily) oral administration of anaprazole sodium enteric-coated tablet were safe and well tolerated...
April 17, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38628396/the-efficacy-and-safety-of-vonoprazan-in-quadruple-therapy-for-helicobacter-pylori-eradication-a-comparative-study
#6
JOURNAL ARTICLE
Xiaoduan Zhuang, Huiyue Jiang, Dandan Jin, Meiling Sun, Zhenwu Wang, Xinying Wang
BACKGROUND: The efficacy and optimal dose of the new acid-suppressant vonoprazan (VPZ) for quadruple therapy remain uncertain. This study aimed to compare the efficacy and safety of 20 mg VPZ daily (VOD) and 20 mg VPZ twice daily (VTD) with a proton pump inhibitor (PPI) twice daily in quadruple therapy. METHODS: We retrospectively analyzed the data of 954 patients treated with quadruple therapy to eradicate Helicobacter pylori . Eradication rates and adverse events were compared between the VOD and VTD groups, and between the VOD and PPI groups...
2024: Gastroenterology Report
https://read.qxmd.com/read/38628394/long-term-course-of-untreated-asymptomatic-esophageal-eosinophilia-and-minimally-symptomatic-eosinophilic-esophagitis
#7
JOURNAL ARTICLE
Yasuhiko Abe, Ryosuke Kikuchi, Yu Sasaki, Naoko Mizumoto, Makoto Yagi, Yusuke Onozato, Takahiro Watabe, Hiroki Goto, Takahiro Miura, Ryou Sato, Minami Ito, Hiroko Tsuchiya, Yoshiyuki Ueno
Background and study aims The long-term course of untreated asymptomatic esophageal eosinophilia (aEE) and minimally symptomatic eosinophilic esophagitis (mEoE) are not well understood. This study aimed to clarify this course. Patients and methods A total of 36 patients with EE who were endoscopically followed up for more than 5 years, and who underwent more than one endoscopy evaluation after the first diagnosis, were investigated. These patients were divided into two groups according to the presence or absence of the continuous treatment: no treatment group (NT group, n=22) and proton pump inhibitor/potassium competitive acid blocker group (Tx group, n=14)...
April 2024: Endoscopy International Open
https://read.qxmd.com/read/38626640/primary-pyloroduodenal-tuberculosis-presenting-as-gastric-outlet-obstruction-a-case-report
#8
Molla Asnake Kebede, Sisay Mengistu Mohammed, Dessalegn Woretaw Ayehu, Yilkal Teshome Numaro, Woineab Mengista Tadeg, Zerubabel Girma Tesso
INTRODUCTION AND IMPORTANCE: Gastric Outlet Obstruction (GOO) is a clinical syndrome due to mechanical obstruction of the gastric outlet near the antrum. The incidence of GOO is not known adequately; however, it is estimated that its incidence has declined in recent years as the incidence of peptic ulcer disease, which is the common cause of GOO, has been declining recently due to the use of proton pump inhibitor (PPI). The objective of this case report to highlight the importance of consideration of TB as a cause of GOO by affecting the duodenal wall and nearby lymph node enlargement...
April 6, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38624107/longitudinal-microbiome-changes-in-children-exposed-to-proton-pump-inhibitors
#9
JOURNAL ARTICLE
Yanjia Jason Zhang, Sarah Connearney, Lisa Hester, Maritha Du, Andrea Catacora, Anna Akkara, Anna Wen, Lynn Bry, Eric J Alm, Rachel Rosen
INTRODUCTION: Proton pump inhibitor (PPI) use has been associated with an increased risk of gastrointestinal and upper respiratory infections in children. There are limited longitudinal data on the effect of PPI in children. The goal of this prospective observational study was to compare the stool and oropharyngeal microbiome of children before and after starting PPIs. METHODS: We prospectively recruited participants from a gastroenterology clinic. Consented pariticpants provided stool samples and oropharyngeal swabs at baseline and after eight weeks of PPI therapy...
April 16, 2024: Clinical and Translational Gastroenterology
https://read.qxmd.com/read/38623060/long-term-outcome-of-asymptomatic-esophageal-eosinophilia
#10
JOURNAL ARTICLE
Yugo Suzuki, Yorinari Ochiai, Daisuke Kikuchi, Mako Koseki, Kenichi Ohashi, Shu Hoteya
BACKGROUND/AIMS: : Asymptomatic esophageal eosinophilia (aEE), characterized by eosinophil infiltration in the esophagus without clinical symptoms, has been reported as a precursor of eosinophilic esophagitis (EoE). Nevertheless, no report exists on the long-term clinical course of the disease. Therefore, this study aimed to investigate the long-term clinical course of aEE over 5 years, including the symptomatic conversion rate and the effect of treatments. METHODS: : We reviewed 28 patients with aEE who had been followed up for over 5 years with endoscopic monitoring...
April 16, 2024: Gut and Liver
https://read.qxmd.com/read/38622898/impact-of-concurrent-medications-on-the-outcome-of-immunotherapy-in-non-small-cell-lung-carcinoma
#11
JOURNAL ARTICLE
Jun Yamada, Takafumi Fukui, Atsuhiko Yatani, Chihiro Mimura, Kiyoko Fukuda, Daisuke Hazama, Naoko Katsurada, Tatsuya Nagano, Masatsugu Yamamoto, Motoko Tachihara
BACKGROUND: There have been reports on the impact of concurrent drugs on the outcome of immunotherapy for non-small cell lung carcinoma (NSCLC). However, the effect of some drugs, such as antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), has not been clarified in patients with NSCLC. In the present study, we aimed to assess the association between concurrent drugs and the outcomes of immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy for patients with advanced NSCLC...
April 15, 2024: Thoracic Cancer
https://read.qxmd.com/read/38622462/differences-between-patients-with-heartburn-refractory-to-vonoprazan-and-those-refractory-to-proton-pump-inhibitors
#12
JOURNAL ARTICLE
Tomoaki Matsumura, Michiko Sonoda, Kenichiro Okimoto, Hang Viet Dao, Satsuki Takahashi, Naoki Akizue, Ryosuke Horio, Chihiro Goto, Akane Kurosugi, Tatsuya Kaneko, Yuki Ohta, Takashi Taida, Atsuko Kikuchi, Mai Fujie, Jun Kato, Naoya Kato
BACKGROUND: Vonoprazan, a potassium-competitive acid blocker, demonstrates more potent acid inhibition than proton pump inhibitors (PPIs). This study aimed to evaluate the effect of vonoprazan in patients with unproven gastroesophageal reflux disease (GERD) by comparing patients with vonoprazan-refractory heartburn with those with PPI-refractory heartburn. METHODS: This study included 104 consecutive patients with vonoprazan- or PPI-refractory heartburn (52 patients each), no erosive esophagitis on endoscopy and who underwent combined multichannel intraluminal impedance-pH (MII-pH) testing with vonoprazan/PPI discontinuation...
April 15, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38619123/proton-pump-inhibitors-and-risk-of-severe-covid-19-in-older-people
#13
JOURNAL ARTICLE
Baptiste Gramont, Sophie Fayolle, Diva Beltramin, Nisrine Bidat, Julie Boudet, Robin Chaux, Lucile Grange, Mathilde Barrau, Amandine Gagneux-Brunon, Pascal Cathébras, Martin Killian, Elisabeth Botelho-Nevers, Thomas Célarier
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 is a viral respiratory infection that can cause systemic disorders and lead to death, particularly in older people. Proton pump inhibitors (PPIs) increase the risk of enteric and lung infections. Considering the broad use of PPIs in older people, the potential role of PPIs in COVID-19 could be of dramatic significance. The objective of our study was to evaluate the link between PPIs and severe COVID-19 in older people. METHOD: We performed a retrospective cohort study, including all patients aged ≥65, hospitalised for a diagnosis of COVID-19...
April 1, 2024: Age and Ageing
https://read.qxmd.com/read/38618424/intussusception-of-heterotopic-gastric-mucosa-in-the-transverse-colon-a-rare-cause-of-perforation-and-bleeding
#14
Sho Fujiwara, Ryuichi Nishimura, Nozomi Koyamada
Heterotopic gastric mucosa in the colorectal region is a rare condition and can be found throughout the gastrointestinal tract. Intussusception in adults is mostly associated with adenocarcinoma and requires prompt surgical intervention, especially in cases of intestinal perforation. Our case report demonstrates a cecal perforation caused by the intussusception of heterotopic gastric mucosa within the transverse colon. The patient presented with substantial hematochezia. Despite the challenges of diagnosing this condition preoperatively and in the ICU, accurate pathologic evaluation is important...
March 2024: Curēus
https://read.qxmd.com/read/38615498/drug-induced-osteoporosis-and-mechanisms-of-bone-tissue-regeneration-through-trace-elements
#15
REVIEW
Nayara de Souza da Costa, Luíza Siqueira Lima, Maria Eduarda Andrade Galiciolli, Deborah Helen Fabiano Ribeiro, Milena Mariano Ribeiro, Gisele de Paula Júlia Garica, Isabela Saragioto Marçal, Juliana Ferreira da Silva, Meire Ellen Pereira, Cláudia Sirlene Oliveira, Izonete Cristina Guiloski
Osteoporosis is associated with an imbalance in bone formation, with certain drugs used in disease treatment being implicated in its development. Supplementation with trace elements may contribute to bone regeneration, offering an alternative approach by enhancing bone mineral density (BMD) and thereby thwarting the onset of osteoporosis. This review aims to assess the mechanisms through which trace elements such as copper (Cu), iron (Fe), selenium (Se), manganese (Mn), and zinc (Zn) are linked to increased bone mass, thus mitigating the effects of pharmaceuticals...
April 4, 2024: Journal of Trace Elements in Medicine and Biology
https://read.qxmd.com/read/38612496/impact-of-stat6-variants-on-the-response-to-proton-pump-inhibitors-and-comorbidities-in-patients-with-eosinophilic-esophagitis
#16
JOURNAL ARTICLE
Paula Soria-Chacartegui, Marcos Navares-Gómez, Francisca Molina-Jiménez, Emilio J Laserna-Mendieta, Laura Arias-González, Pedro Majano, Sergio Casabona, Alfredo J Lucendo, Francisco Abad-Santos, Cecilio Santander, Pablo Zubiaur
Proton pump inhibitors (PPIs) are the first-line drug for eosinophilic esophagitis (EoE), although it is estimated that there is a lack of histological remission in 50% of patients. This research aimed to identify pharmacogenetic biomarkers predictive of PPI effectiveness and to study their association with disease features. Peak eosinophil count (PEC) and the endoscopic reference score (EREFS) were determined before and after an eight-week PPI course in 28 EoE patients. The impact of the signal transducer and activator of transcription 6 ( STAT6 ), CYP2C19 , CYP3A4 , CYP3A5, and ABCB1 genetic variations on baseline PEC and EREFS, their reduction and histological response, and on EoE symptoms and comorbidities was analyzed...
March 26, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38610738/proton-pump-inhibitors-and-cancer-risk-a-comprehensive-review-of-epidemiological-and-mechanistic-evidence
#17
REVIEW
Ibrahim O Sawaid, Abraham O Samson
Background: Proton pump inhibitors (PPIs) are commonly prescribed long-acting drugs used to treat acid reflux, gastroesophageal reflux disease (GERD), and peptic ulcers. Recently, concerns have been raised about their safety, particularly due to the association between long-term PPI use and cancer development. Multiple comprehensive studies have consistently suggested a noteworthy link between prolonged PPI usage and an increased risk of developing gastric, esophageal, colorectal, and pancreatic cancers, yet the precise underlying mechanism remains elusive...
March 28, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38609893/comparison-of-vonoprazan-dual-therapy-quadruple-therapy-and-standard-quadruple-therapy-for-helicobacter-pylori-infection-in-hainan-a-single-center-open-label-non-inferiority-randomized-controlled-trial
#18
JOURNAL ARTICLE
Chen Chen, Daya Zhang, Shimei Huang, Fan Zeng, Da Li, Xiaodong Zhang, Runxiang Chen, Shiju Chen, Jun Wang, Feihu Bai
OBJECTIVE: To compare the potential efficacy and safety of dual therapy and quadruple therapy with vonoprazan (VPZ) as well as the standard quadruple therapy of proton pump inhibitor (PPI) for the eradication of Helicobacter pylori (Hp) infection in Hainan province. METHODS: A single-centre, non-blinded, non-inferiority randomized controlled trial was conducted at the outpatient department of gastroenterology at the Second Affiliated Hospital of Hainan Medical University from June 2022 to February 2023...
April 12, 2024: BMC Gastroenterology
https://read.qxmd.com/read/38607993/vonoprazan-is-not-inferior-to-proton-pump-inhibitors-in-bismuth-containing-quadruple-therapy-for-helicobacter-pylori-eradication-a-meta-analysis-of-10-studies-from-east-asia
#19
JOURNAL ARTICLE
Yujie Cheng, Lin Yang, Si Xu, Chong Zhang
OBJECTIVE: To investigate the efficacy and safety of vonoprazan based bismuth-containing quadruple therapy (VBCQ) in eradicating Helicobacter pylori (Hp). MATERIALS AND METHODS: The VBCQ and the proton pump inhibitor-based bismuth-containing quadruple regimen (PBCQ) were compared by retrieving relevant studies in Pubmed, Embase, Cochrane Library, CNKI, and Wanfang data. Combined analysis was performed with risk ratio (RR) and 95% CI as effect values. RESULTS: A total of 10 studies were enrolled, including 7 randomized controlled trials and 3 cohort studies...
April 12, 2024: Journal of Clinical Gastroenterology
https://read.qxmd.com/read/38607520/enzalutamide-understanding-and-managing-drug-interactions-to-improve-patient-safety-and-drug-efficacy
#20
REVIEW
Brandon W Lennep, Jesse Mack, Srinivasu Poondru, Elizabeth Hood, Brooke D Looney, Monique Williams, Judeth J Bianco, Alicia K Morgans
Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and a strong inducer of CYP3A4. It was also shown to be a mild inhibitor of the efflux transporter P-glycoprotein in patients with prostate cancer. Enzalutamide is primarily metabolized by CYP3A4 and CYP2C8. The risk of enzalutamide drug interactions arises primarily when it is coadministered with other drugs that interact with these CYPs, including CYP3A4...
April 12, 2024: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
keyword
keyword
13516
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.